[
  {
    "ts": null,
    "headline": "Tracking Al Gore's Generation Investment Management Portfolio - Q2 2025 Update",
    "summary": "Generation IMâs Q2 2025 portfolio value declined to $15.73B, with 37 positions. Click here to read more about the portfolio's new stakes and increases.",
    "url": "https://finnhub.io/api/news?id=15864115a6c895d4c5f1698ffec1e422e4099bb9e0ffca15fa48d99680b80f65",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755553497,
      "headline": "Tracking Al Gore's Generation Investment Management Portfolio - Q2 2025 Update",
      "id": 136414758,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/534971566/image_534971566.jpg?io=getty-c-w1536",
      "related": "BDX",
      "source": "SeekingAlpha",
      "summary": "Generation IMâs Q2 2025 portfolio value declined to $15.73B, with 37 positions. Click here to read more about the portfolio's new stakes and increases.",
      "url": "https://finnhub.io/api/news?id=15864115a6c895d4c5f1698ffec1e422e4099bb9e0ffca15fa48d99680b80f65"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences: Gradually Winning My Investment Heart",
    "summary": "Edwards Lifesciences Corporation refocuses on heart valve therapies, driving growth with innovation, FDA approvals, and strong financials. Click for my EW update.",
    "url": "https://finnhub.io/api/news?id=b4d68fe4248c56b025ddc5fab6b1c9adb3fcd37cea6de4d58ff3eb42b855e030",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755534556,
      "headline": "Edwards Lifesciences: Gradually Winning My Investment Heart",
      "id": 136412120,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193239681/image_2193239681.jpg?io=getty-c-w1536",
      "related": "BDX",
      "source": "SeekingAlpha",
      "summary": "Edwards Lifesciences Corporation refocuses on heart valve therapies, driving growth with innovation, FDA approvals, and strong financials. Click for my EW update.",
      "url": "https://finnhub.io/api/news?id=b4d68fe4248c56b025ddc5fab6b1c9adb3fcd37cea6de4d58ff3eb42b855e030"
    }
  },
  {
    "ts": null,
    "headline": "Becton, Dickinson and Company Stock: Is Wall Street Bullish or Bearish?",
    "summary": "Despite Becton, Dickinson and Company’s weak performance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=b6c7331a555debf7e0931d559c40af154d84d3d0262e959ab35e42f034b78796",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755533936,
      "headline": "Becton, Dickinson and Company Stock: Is Wall Street Bullish or Bearish?",
      "id": 136417224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BDX",
      "source": "Yahoo",
      "summary": "Despite Becton, Dickinson and Company’s weak performance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=b6c7331a555debf7e0931d559c40af154d84d3d0262e959ab35e42f034b78796"
    }
  },
  {
    "ts": null,
    "headline": "Becton, Dickinson: Great Time To Buy This Dividend Aristocrat",
    "summary": "Becton, Dickinson: Great Time To Buy This Dividend Aristocrat",
    "url": "https://finnhub.io/api/news?id=5c9ce7abea018f11a28b543514422bbb1c69b5c498f0867a23cebaaf52defd04",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755504000,
      "headline": "Becton, Dickinson: Great Time To Buy This Dividend Aristocrat",
      "id": 136406677,
      "image": "",
      "related": "BDX",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5c9ce7abea018f11a28b543514422bbb1c69b5c498f0867a23cebaaf52defd04"
    }
  },
  {
    "ts": null,
    "headline": "Surgical Equipment & Consumables - Diversified Stocks Q2 Results: Benchmarking BD (NYSE:BDX)",
    "summary": "Let’s dig into the relative performance of BD (NYSE:BDX) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - diversified earnings season.",
    "url": "https://finnhub.io/api/news?id=3e23a59b29be46d84cf516bfc145dca7ad2f5040f9ede0f1fd443429a85e0da0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755488073,
      "headline": "Surgical Equipment & Consumables - Diversified Stocks Q2 Results: Benchmarking BD (NYSE:BDX)",
      "id": 136408968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BDX",
      "source": "Yahoo",
      "summary": "Let’s dig into the relative performance of BD (NYSE:BDX) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - diversified earnings season.",
      "url": "https://finnhub.io/api/news?id=3e23a59b29be46d84cf516bfc145dca7ad2f5040f9ede0f1fd443429a85e0da0"
    }
  }
]